INmune Bio Shows p<0.01 White Matter Myelin Gains in Phase 2 Alzheimer’s Study
INMB•INmune Bio reported statistically significant treatment-related improvements in white matter myelin integrity (p<0.01) and cortical microstructure at Week 24 in its Phase 2 study of XPro1595 in early Alzheimer’s disease. Larger effects emerged in biomarker-enriched patients and will appear in a July 12 AAIC poster ahead of a planned Phase 2b/3 program.
1. Positive Phase 2 Imaging Results
INmune Bio’s Phase 2 MINDFuL study of XPro1595 in early Alzheimer’s disease demonstrated statistically significant improvements in white matter myelin integrity (p<0.01) at Week 24 in the modified intent-to-treat population. Advanced MRI analyses, including chi-separation and cortical disarray measurement, showed concordant treatment effects and larger responses in biomarker-enriched patients.
2. AAIC Presentation and Development Plans
Expanded imaging analyses will be presented on July 12 at the Alzheimer’s Association International Conference in London. The poster will cover longitudinal data, subgroup findings, and mechanistic imaging context, supporting a planned seamless Phase 2b/3 registrational program leveraging FDA Fast Track designation.
